

The Jacobs Institute Newsletter

A Dose of Medical Innovation

Issue: #22

August 2019



Precision Medicine is First Topic in JI's new Future of Medicine Lecture Series



IN PHOTO: Bill Maggio, chief executive officer, JI; Dr. David Spetzler, president & chief scientific officer, Caris Life Sciences; Dr. L. Nelson Hopkins, chief scientific officer, JI; Dr. Adnan Siddiqui, chief medical officer, JI.

On July 18, the Jacobs Institute (JI) drew an audience of nearly 400 people to hear from David Spetzler, MS, PhD, MBA, an innovator in precision medicine, whose work provided the first tumor profiling and targeted, personalized treatments for cancer. The free lecture was the first in our Future of Medicine Series, continuing the conversation about what is possible in the next quarter-century in medicine—new technologies and treatments across all fields of medicine and healthcare. The series follows the release of [The Future of Medicine](#) book in 2017.

[You can watch Dr. Spetzler's lecture by clicking HERE.](#)

Mr. Jeremy M. Jacobs, chairman of the JI board of directors, said, "We launched The Future of Medicine project with the hope that it would spark

dialogue and the exchange of ideas. It is gratifying to see that our vision has come to fruition. This lecture series is yet another way for our medical community to engage with the exciting and thought-provoking content of *The Future of Medicine*."

The inaugural lecture speaker was Dr. Spetzler, who is president and chief scientific officer of [Caris Life Sciences](#)

He shared his deep knowledge of next-generation DNA sequencing, exosome biology, bioinformatics, and broad-based molecular profiling. Caris was the first company to offer comprehensive tumor molecular profiling services to help cancer patients by better informing their course of treatment through understanding their unique tumor biology. Dr. Spetzler engaged the audience that filled the M&T Auditorium at University at Buffalo's (UB's) Jacobs School of Medicine and Biomedical Sciences.



Jl chief executive officer, Bill Maggio, said, "The Jacobs Institute has united thought leaders and led the conversation around the next frontier in medicine and healthcare. As I have stressed-through my involvement on the medical campus-collaboration amongst all organizations is paramount to our shared success." Maggio further said, "Mr. Jeremy M. Jacobs' strong commitment to medicine, and to Buffalo, is evidenced by the JI commissioning *The Future of Medicine* book and through this free lecture series, held at the University at Buffalo's first-class medical school which bears his name. The series aims to attract medical innovators who are spearheading new discoveries, treatments, and programs that will change the course of our lives in the near future."

L. Nelson Hopkins, MD, FACS, JI's chief scientific officer, said, "We are fortunate to have someone of Dr. Spetzler's caliber join us in Buffalo. His work empowers and advances the molecular analysis of tumor tissue at a magnitude and complexity unseen before, allowing personalized targeted therapy for cancer previously impossible. This is a look into the future treatment of and cure for cancer, which is actually beginning to happen today."

"Cutting edge precision medications for cancer, such as those pioneered by Dr. Spetzler, were highlighted in *The Future of Medicine*. Combining novel medical devices and patient-specific medications, while harnessing the power of big data and artificial intelligence, will drastically alter how we identify, diagnose, and treat diseases. The JI takes a global look at new forces propelling innovation," said Adnan Siddiqui, MD, PhD, FAHA, FAANS, chief medical officer of the JI.



In 2017, the JI released *The Future of Medicine*, which provides a glimpse into the next quarter-century of medicine and healthcare, featuring rapid technological, scientific, and computing advancements that are certain to impact the ever-changing industry. The book was created by a group of futurists-with decades of experience assessing the current state and future possibilities of our society-through months of interviews, conferences, and research.

The Jacobs Institute mission is to accelerate the development of next-generation technologies in vascular medicine through collisions of physicians, engineers, entrepreneurs, and industry.

Our vision is to improve the treatment of vascular disease in Western New

York and the world, while fostering local economic development, and honoring the memory of Lawrence D. Jacobs, MD.

Located in the heart of the Buffalo Niagara Medical Campus (BNMC) in downtown Buffalo, the Jacobs Institute is positioned between University at Buffalo's Clinical and Translational Research Center (CTRC) and Kaleida Health's Gates Vascular Institute (GVI).



The JI is uniquely positioned to foster collaboration of our key partners. We have the right people in the right place at the right time.

Come innovate with us.

Please visit [the JI web site](#)

Sincerely,The Jacobs Institute

